Earnings Release • Nov 21, 2019
Earnings Release
Open in ViewerOpens in native device viewer

Valence, November 21, 2019 at 6:00 pm CET - Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) ("Amplitude" or the "Group"), a leading French player on the global surgical technology market for lower-limb orthopedics, announces its sales for the first quarter of its 2019-20 financial year.
Olivier Jallabert, Chairman and CEO of Amplitude Surgical, said: "In the first quarter of our 2019-20 financial year, Amplitude Surgical posted growth of 6.0% at constant exchange rates, driven by an excellent international performance, in particular by subsidiaries. Sales generated in the United States were up 86% compared to the same quarter last year. Novastep, meanwhile, is continuing to ramp-up and now accounts for approximately 10% of total Group revenue, with over 40% growth over the period."
| Q1 2019-20 sales | 30/09/2019 | 30/09/2018 | Change | Change |
|---|---|---|---|---|
| In thousands of euros - IFRS | at current exchange rates |
at constant exchange rates |
||
| France | 12,091 | 11,642 | +3.9% | +3.9% |
| International | 8,745 | 7,895 | +10.8% | +9.2% |
| o/w subsidiaries | 6,815 | 5,877 | +15.9% | +13.9% |
| o/w distributors | 1,930 | 2,017 | -4.3% | -4.3% |
| Total | 20,837 | 19,537 | 6.7% | 6.0% |
In the first quarter of its 2019-20 financial year (July-September), Amplitude Surgical reported sales of €20.8 million, up 6.7% and 6.0% at constant exchange rates.


• Novastep, which markets innovative solutions for foot and ankle surgery, recorded buoyant growth of 39.7% at constant exchange rates, with quarterly sales of €2.0 million, primarily driven by the United States (+83.9% at constant exchange rates). The proportion of sales generated abroad has increased to over 65%, and Novastep now accounts for 9.4% of the Group's total sales.
ANVISA (Agencia Nacional de Vigilancia Sanitaria), the Brazilian regulatory authority for the registration of medical devices, approved on September 9, 2019 the marketing authorization for the Integral Revision hip prosthesis; this new registration allows Amplitude Latam to expand the product offering in Brazil, in association with the Saturn II double mobility acetabulum1 , registered last May.
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2019, Amplitude Surgical had a workforce of 436 employees and recorded sales of c.103 million euros.
Amplitude Surgical Philippe Garcia CFO [email protected] +33 (0)4 75 41 87 41
NewCap Investor Relations Théodora Xu [email protected] +33 (0)1 44 71 20 42
NewCap Media Relations Nicolas Merigeau [email protected] +33 (0)1 44 71 98 55

1 Cotyloid cavity.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.